60 DEGREES PHARMACEUTICALS, INC. 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a company at a critical crossroads between a high-growth commercial pivot and a classic micro-cap liquidity struggle. On one hand, the expansion of Arakoda's utility into the babesiosis market and the growth in research contract revenue signal a viable path toward a larger addressable market. The operational shift toward a 'platform' approach reduces the traditional binary risk associated with drug discovery by utilizing an already approved molecule. However, the financial reality is stark: the company is burning cash at a rate that necessitates frequent equity issuance, which continues to erode shareholder value through dilution. The investment thesis currently hinges on the Q3 2026 clinical data for babesiosis; a positive result could validate the $245 million market estimate and attract the institutional funding needed to stabilize the balance sheet. Until then, investors must weigh the potential for a massive clinical breakthrough against the very real possibility of further capital impairment.